Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Proxalutamide  COVID-19 treatment studies for Proxalutamide  C19 studies: Proxalutamide  Proxalutamide   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 proxalutamide studies
00.250.50.7511.251.51.752+McCoy (DB RCT)80%0.20 [0.01-4.13]death0/1342/134Improvement, RR [CI]TreatmentControlCadegiani (DB RCT)92%0.08 [0.04-0.17]viral+7/17134/66Cadegiani (DB RCT)63%0.37 [0.02-8.85]death0/751/102Tau​2 = 0.00; I​2 = 0.0%Early treatment91%0.09 [0.04-0.19]7/38037/30291% improvementCadegiani (DB RCT)84%0.16 [0.11-0.24]death35/317197/328Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment84%0.16 [0.11-0.24]35/317197/32884% improvementAll studies86%0.14 [0.10-0.20]42/697234/63086% improvement4 proxalutamide COVID-19 studiesc19proxalutamide.com Sep 26, 2021Tau​2 = 0.01; I​2 = 3.6%; Z = 11.45Effect extraction pre-specifiedFavors proxalutamideFavors control 00.250.50.7511.251.51.752+McCoy (DB RCT)80%0.20 [0.01-4.13]0/1342/134Improvement, RR [CI]TreatmentControlCadegiani (DB RCT)63%0.37 [0.02-8.85]0/751/102Tau​2 = 0.00; I​2 = 0.0%Early treatment73%0.27 [0.03-2.39]0/2093/23673% improvementCadegiani (DB RCT)84%0.16 [0.11-0.24]35/317197/328Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment84%0.16 [0.11-0.24]35/317197/32884% improvementAll studies84%0.16 [0.12-0.22]35/526200/56484% improvement3 proxalutamide COVID-19 mortality resultsc19proxalutamide.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 11.12Favors proxalutamideFavors control 00.250.50.7511.251.51.752+McCoy (DB RCT)91%0.09 [0.03-0.27]hosp.3/13435/134Improvement, RR [CI]TreatmentControlCadegiani (DB RCT)86%0.14 [0.03-0.60]hosp.2/7519/102Tau​2 = 0.00; I​2 = 0.0%Early treatment89%0.11 [0.04-0.27]5/20954/23689% improvementAll studies89%0.11 [0.04-0.27]5/20954/23689% improvement2 proxalutamide COVID-19 hospitalization resultsc19proxalutamide.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 4.86Favors proxalutamideFavors control 00.250.50.7511.251.51.752+McCoy (DB RCT)80%0.20 [0.01-4.13]death0/1342/134Improvement, RR [CI]TreatmentControlCadegiani (DB RCT)63%0.37 [0.02-8.85]death0/751/102Tau​2 = 0.00; I​2 = 0.0%Early treatment73%0.27 [0.03-2.39]0/2093/23673% improvementCadegiani (DB RCT)84%0.16 [0.11-0.24]death35/317197/328Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment84%0.16 [0.11-0.24]35/317197/32884% improvementAll studies84%0.16 [0.12-0.22]35/526200/56484% improvement3 proxalutamide COVID-19 serious outcomesc19proxalutamide.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 11.12Effect extraction pre-specifiedFavors proxalutamideFavors control 00.250.50.7511.251.51.752+Cadegiani (DB RCT)92%0.08 [0.04-0.17]viral+7/17134/66Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment92%0.08 [0.04-0.17]7/17134/6692% improvementAll studies92%0.08 [0.04-0.17]7/17134/6692% improvement1 proxalutamide COVID-19 viral clearance resultc19proxalutamide.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 6.51Favors proxalutamideFavors control 00.250.50.7511.251.51.752+McCoy (DB RCT)80%0.20 [0.01-4.13]death0/1342/134Improvement, RR [CI]TreatmentControlCadegiani (DB RCT)92%0.08 [0.04-0.17]viral+7/17134/66Cadegiani (DB RCT)63%0.37 [0.02-8.85]death0/751/102Tau​2 = 0.00; I​2 = 0.0%Early treatment91%0.09 [0.04-0.19]7/38037/30291% improvementCadegiani (DB RCT)84%0.16 [0.11-0.24]death35/317197/328Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment84%0.16 [0.11-0.24]35/317197/32884% improvementAll studies86%0.14 [0.10-0.20]42/697234/63086% improvement4 proxalutamide COVID-19 Randomized Controlled Trialsc19proxalutamide.com Sep 26, 2021Tau​2 = 0.01; I​2 = 3.6%; Z = 11.45Effect extraction pre-specifiedFavors proxalutamideFavors control 00.250.50.7511.251.51.752+McCoy (DB RCT)80%0.20 [0.01-4.13]0/1342/134Improvement, RR [CI]TreatmentControlCadegiani (DB RCT)63%0.37 [0.02-8.85]0/751/102Tau​2 = 0.00; I​2 = 0.0%Early treatment73%0.27 [0.03-2.39]0/2093/23673% improvementCadegiani (DB RCT)84%0.16 [0.11-0.24]35/317197/328Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment84%0.16 [0.11-0.24]35/317197/32884% improvementAll studies84%0.16 [0.12-0.22]35/526200/56484% improvement3 proxalutamide COVID-19 RCT mortality resultsc19proxalutamide.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 11.12Favors proxalutamideFavors control 00.250.50.7511.251.51.752+McCoy (DB RCT)80%0.20 [0.01-4.13]death0/1342/134Improvement, RR [CI]TreatmentControlCadegiani (DB RCT)92%0.08 [0.04-0.17]viral+7/17134/66Tau​2 = 0.00; I​2 = 0.0%Early treatment92%0.08 [0.04-0.18]7/30536/20092% improvementAll studies92%0.08 [0.04-0.18]7/30536/20092% improvement2 proxalutamide COVID-19 peer reviewed trialsc19proxalutamide.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 6.57Effect extraction pre-specifiedFavors proxalutamideFavors control 00.250.50.7511.251.51.752+McCoy (DB RCT)80%0.20 [0.01-4.13]death0/1342/134Improvement, RR [CI]TreatmentControlMcCoy (DB RCT)97%0.03 [0.00-0.47]ventilation0/13417/134McCoy (DB RCT)91%0.09 [0.03-0.27]hosp.3/13435/134Cadegiani (DB RCT)92%0.08 [0.04-0.17]viral+7/17134/66Cadegiani (DB RCT)77%0.23 [0.16-0.33]no recov.30/17150/66Cadegiani (DB RCT)63%0.37 [0.02-8.85]death0/751/102Cadegiani (DB RCT)90%0.10 [0.01-1.84]ventilation0/755/102Cadegiani (DB RCT)86%0.14 [0.03-0.60]hosp.2/7519/102Cadegiani (DB RCT)84%0.16 [0.11-0.24]death35/317197/328Cadegiani (DB RCT)89%0.11 [0.04-0.31]ventilation4/31737/328Cadegiani (DB RCT)78%0.22 [0.16-0.31]progression36/317168/328Cadegiani (DB RCT)72%0.28 [0.21-0.37]no recov.46/317173/328proxalutamide COVID-19 outcomesc19proxalutamide.com Sep 26, 2021Favors proxalutamideFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit